Article

ifa Systems acquires inoveon

ifa Systems AG has acquired inoveon Corp. ifa Systems provides ophthalmology-related software applications, including an electronic health record system that has been adopted in Europe and Latin America and now has been introduced into the North American and Asian markets. inoveon Corp. is a medical services company focused on managing diabetic eye disease, clinical research, and development.

Oklahoma City, OK-ifa Systems AG has acquired inoveon Corp.

ifa Systems provides ophthalmology-related software applications, including an electronic health record system that has been adopted in Europe and Latin America and now has been introduced into the North American and Asian markets. inoveon Corp. is a medical services company focused on managing diabetic eye disease, clinical research, and development.

The two companies previously have collaborated in developing open clinical and health information technology standards. The merger is expected to broaden ifa’s product line and distribution structure and further its international market share in 17 countries managing more than 70 million patients’ data.

The merger also means that Oklahoma City will become a hub for international telemedicine activities for inoveon, including service development and consulting activities. The inoveon platform will be extended, and its services will expand to include new ones for ifa’s installed client base.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.